What Tetris Pharma does

Tetris Pharma was a UK-based niche specialty pharmaceutical company that operated from its founding in 2020 until formally ceasing operations on 1st October 2025. The company was registered as Tetris Pharma Ltd (registration number 12548259) and headquartered at Chesterford Research Park in Little Chesterford, Saffron Walden, UK. Its stated strategic intent was to build a European platform for marketing a range of prescription pharmaceutical products.

The company commercialized a single core product, Ogluo, a prescription pharmaceutical indicated for diabetes management. It served two primary customer segments on a horizontal basis: end-user patients requiring access to Ogluo, and healthcare professionals (HCPs) who prescribed or recommended the product. The firm employed between 11 and 50 staff and operated as a privately-held limited company throughout its existence, with leadership including Leslie Galloway (Chairman) and Maddy Kennedy (CFO). No public funding rounds, acquisitions, AI/ML capabilities, or proprietary technology disclosures are present in the available data, consistent with a pure commercial rather than R&D-driven specialty pharma business.

Effective 1st October 2025, Tetris Pharma formally ceased operations. All outstanding matters, medical information requests, product complaints, adverse event reporting, and general enquiries have been transferred to Arecor Therapeutics, which now serves as the residual handler for Ogluo-related business and patient/HCP communications. The company website at tetrispharma.com directs all stakeholders to Arecor's contact channels.

Name

Tetris Pharma

Legal name

Tetris Pharma Ltd

Website

https://tetrispharma.com/

Company type

Private

Founded year

2020

Operating status

Closed

Headcount range

11–50 employees

Short description

Tetris Pharma was a UK-based specialty pharmaceutical company that commercialized Ogluo, a single prescription diabetes product, to patients and healthcare professionals before ceasing operations on 1st October 2025.

Ownership category

akta.pro rank

Product category

Specialty Pharmaceuticals

NAICS

Pharmaceutical Preparation Manufacturing (325412)

SIC

Pharmaceutical Preparations (2834)

akta.pro primary industry

Endocrinology & Reproductive Health Pharmaceuticals (incl. Women’s Health) (HLAIAAAJ)

akta.pro secondary industry

Primary Care & General Medicine Pharmaceuticals (HLAIAAAA)

Keywords

• Specialty pharmaceuticals
• Prescription medicines
• Diabetes medication
• Pharmaceutical marketing
• European pharma platform

Headquarters

HQ city

Marlow

HQ country

United Kingdom

HQ region

Europe

Offices1 record

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Supply Chain, Marketing or Sales, Personnel, Operations

Core offering

Tetris Pharma was a UK-based niche specialty pharmaceutical company that built a European platform to market prescription products, primarily commercializing Ogluo, a pharmaceutical product for diabetes management aimed at patients and healthcare professionals. The company ceased operations effective 1st October 2025, with outstanding matters handled by Arecor Therapeutics.

Product overview

Tetris Pharma operated as a single-product pharmaceutical company offering Ogluo, a medication available to both patients and healthcare professionals. The company formally ceased operations effective October 1, 2025, with medical information, product complaints, and adverse event reporting managed through contact channels listed on their website.

Differentiator

Problem solved

Functional benefit

Products and services

• Ogluo Ogluo is a prescription pharmaceutical product for diabetes management, marketed by Tetris Pharma to patients and healthcare professionals. The company formally ceased operations on 1st October 2025, with outstanding matters referred to Arecor Therapeutics.

Segments2 records

Ideal customer profiles2 records

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Partnerships

One partnership is on record.

• Arecor TherapeuticscoreOthers · 1 October 2025Following Tetris Pharma's cessation of operations effective 1st October 2025, Arecor Therapeutics has taken over handling of all outstanding matters, enquiries, medical information requests, and other business matters previously managed by Tetris Pharma. Contact: [email protected] or +44(0)1223 426060.

Scale indicators1 record

Recent moves3 records

Direct peers

• Zealand Pharma: Danish specialty biopharmaceutical company that developed and commercialised Zegalogue (dasiglucagon), a glucagon rescue product for severe hypoglycemia in diabetes — directly comparable to Tetris Pharma's marketed product Ogluo in therapeutic indication, mechanism and patient segment.
• Xeris Biopharma: US specialty biopharma that developed and commercialised Gvoke, a ready-to-use glucagon rescue product for severe hypoglycemia — a direct competitor to Ogluo in mechanism, indication and prescriber audience.

Broad incumbents

• Novo Nordisk: Global diabetes incumbent selling the full range of insulin and glucagon products (including the GlucaGen glucagon rescue line) across Europe and globally — directly competitive with Tetris in the severe-hypoglycemia rescue category, but operating at vastly greater scale and breadth.
• Eli Lilly: Major diabetes franchise operator with insulin offerings and historical presence in glucagon rescue — overlaps with Tetris Pharma in the diabetes/endocrinology prescribing audience served by Ogluo across European markets.
• Sanofi: Global diabetes incumbent with broad insulin and glucose-rescue portfolios, competing for the same European HCP and patient audiences that Tetris targeted with Ogluo.

Others

• Arecor Therapeutics: UK-based specialty pharmaceutical formulation company now formally responsible for handling Tetris Pharma's outstanding matters, medical information and adverse-event reporting — directly linked as the successor/transition counterparty and itself a UK specialty pharma peer.

Regional players

• Chiesi Farmaceutici: European-headquartered specialty pharmaceutical company marketing prescription products across multiple therapeutic areas including endocrinology — comparable to Tetris Pharma's model of building a European commercial platform for prescription products.
• Recordati: European specialty pharmaceutical group commercialising prescription products across endocrinology and rare-disease categories — comparable to Tetris as a European-focused specialty pharma commercial platform.
• Norgine: European specialty pharmaceutical company marketing prescription products across the UK and continental Europe — a comparable European-focused specialty pharma commercial model to the platform Tetris was building.

Emerging players

• Shield Therapeutics: UK-listed specialty pharmaceutical company commercialising prescription products in focused therapeutic areas — comparable in scale, UK base and specialty-pharma commercial model to Tetris Pharma.

Market position

Strengths1 record

Weaknesses3 records

Competitive moat3 records

Key risks5 records

Key highlights4 records

Customer concentration

Revenue estimate

Valuation estimate

Number of profiles

Profiles2 records

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Tetris Pharma